NVO241227C105000
- 0.13
- 0.000.00%
Novo-Nordisk A/S Newsroom
Jim Cramer Says Novo Nordisk A/S (NVO) Can't Exceed Eli Lilly
Novo Nordisk Is 'Losing Its Pep' in GLP-1 Race: BMO Analyst
U.S. stocks gold mining | Apple's stock price hits new highs consecutively! Sprinting towards a 4 trillion dollar Market Cap; AI Technology stocks continue to be strong, with Palantir and "little NVIDIA" Astera Labs both reaching new highs.
AI technology stocks continue to thrive, with stock prices reaching new highs! Palantir and "little NVIDIA" Astera Labs also hit new records; Apple has reached an all-time high! The total market value has reached 3.9 trillion USD, approaching the 4 trillion USD mark.
Institutions: Inflow for Novo-Nordisk A/S surged 32 times last Friday due to disappointing weight loss drug data providing a buying opportunity.
On December 25, Grizzly Research reported that investment research firm Vanda Research showed that last Friday, Novo-Nordisk A/S saw a net inflow of funds surge 32 times in a single day, climbing from $0.49 million the previous day to $15.6 million, because the disappointing data on its weight loss drug provided a rare opportunity to buy on dips. The data released by Novo-Nordisk A/S indicated that the experimental drug CagriSema only helped patients lose 22.7% of their weight, which fell short of the expected 25%. The stock of Novo-Nordisk A/S dropped by as much as 21% during trading last Friday, reaching $81.5, the lowest level since August 2023.
U.S. stocks closed | The "Santa Claus Rally" has arrived! The three major indices rose about 1%, with the Nasdaq returning to above 0.02 million points; Tesla surged over 7%, and Apple reached a new record Market Cap of 3.9 trillion.
European and American stock and bond markets closed early, with U.S. stocks collectively closing at their daily highs. NVIDIA and other large Technology stocks led the rally, Apple reached a new high again, Broadcom rose over 3%, Goldman Sachs and Morgan Stanley increased by more than 2%, the Chinese concept Index once rose over 1%, Baosheng Media Group surged by 310%, NIO and YUM CHINA rose more than 3%.
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
The Stoxx 600 Index rose before the Christmas holiday, with Novo-Nordisk A/S increasing by about 6%.
Trading on Christmas Eve was shortened, and European stocks rose on Tuesday. The Stoxx600 Index increased by 0.2%. Novo-Nordisk A/S (NVO.US) resumed its upward momentum, rising to the top of the Stoxx600 Index with an increase of about 6%. The UK FTSE100 Index closed up 34 points or 0.4%, at 8,136 points. The DEGUODAXZHISHU was closed. The France CAC40 Index closed up 10 points or 0.1%, at 7,282 points.
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
Novo Nordisk Shares Rally Despite Setback in Obesity Drug Trial Results
FDA Approves First Generic of Novo Nordisk's Victoza
Novo-Nordisk A/S Options Spot-On: On December 23rd, 100.63K Contracts Were Traded, With 599.3K Open Interest
On December 23rd ET, $Novo-Nordisk A/S(NVO.US)$ had active options trading, with a total trading volume of 100.63K options for the day, of which put options accounted for 46.05% of the total
Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
BMO Capital has lowered the Target Price for Novo-Nordisk A/S to $105.
Gelonghui December 23 | BMO Capital: Downgraded the Target Price of Novo-Nordisk A/S from $156 to $105, maintaining an 'outperform market' rating. (Gelonghui)
Major Bank Rating | TD Cowen: Downgraded Novo-Nordisk A/S Target Price to $105, maintaining "Buy" rating.
On December 23, Glory Holdings reported that TD Cowen has lowered the Target Price for Novo-Nordisk A/S from $155 to $105, maintaining a Buy rating. TD Cowen pointed out that despite the trial results of CagriSema being below expectations, Novo-Nordisk A/S has a strong market position due to its main drugs, the potential of the new CagriSema trials, and a vibrant product line. (Glory Holdings)
BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105
Novo Nordisk Analyst Ratings
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark